4-methyl-heptane-2,3-dione | 99769-42-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-methyl-heptane-2,3-dione
• 英文别名: 4-Methyl-heptan-2,3-dion；4-Methylheptane-2,3-dione；4-methylheptane-2,3-dione
• CAS: 99769-42-3
• 化学式: C₈H₁₄O₂
• 分子量: 142.198
• InChiKey: QAWWOCIHMMAAHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-acetyl-2-methyl-3-propyl-oxirane 在 硫酸 作用下， 生成 4-methyl-heptane-2,3-dione
  参考文献：
  名称：

  Tischtschenko et al., Zhurnal Obshchei Khimii, 1959, vol. 29, p. 809,814; engl. Ausg. S. 795, 799

  摘要：

  DOI：

文献信息

• NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS
  申请人：Saksena Anil K.

  公开号：US20110117057A1

  公开（公告）日：2011-05-19

  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

  本发明披露了具有HCV蛋白酶抑制活性的新化合物，以及制备这些化合物的方法。在另一种实施方式中，本发明披露了包含这些化合物的制药组合物，以及使用它们治疗与HCV蛋白酶相关的疾病的方法。
• BRIDGED BICYCLIC SERINE PROTEASE INHIBITORS
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1404704B9

  公开（公告）日：2008-02-20
• [EN] BRIDGED BICYCLIC SERINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS BICYCLIQUES PONTES DE LA SERINE PROTEASE
  申请人：VERTEX PHARMA

  公开号：WO2003006490A1

  公开（公告）日：2003-01-23

  The present invention relates to peptidomimetic compounds which inhibit serine protease activity, particularly the activity of hepatitis c virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The compounds of this invention have a bridged bicyclic moiety at the P2 position. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by adminstering a composition comprising a compound of this invention.
• [EN] METHOD OF INHIBITING CATHEPSIN ACTIVITY<br/>[FR] PROCEDE D'INHIBITION DE L'ACTIVITE DE CATHEPSINE
  申请人：SCHERING CORP

  公开号：WO2006113942A2

  公开（公告）日：2006-10-26

  [EN] The present invention provides methods of inhibiting cathepsin activity in a subject in need thereof comprising administering to said subject an effective amount of at least one compound of various formulae (e.g., formula I-XXVI) disclosed herein. The present invention also provides methods of treatment of various diseases utilizing the foregoing compounds.
  [FR] L'invention concerne des procédés d'inhibition de l'activité de la cathepsine chez un sujet le nécessitant qui consiste à administrer à ce sujet une quantité efficace d'au moins un composé de diverses formules (par exemple, formule I-XXVI). Cette invention concerne également des procédés de traitement de diverses maladies au moyen des composés susmentionnés.
• Tischtschenko et al., Zhurnal Obshchei Khimii, 1959, vol. 29, p. 809,814; engl. Ausg. S. 795, 799
  作者：Tischtschenko et al.

  DOI：——

  日期：——